Picture BIO Deutschland German Biotech Days 2019 Würzburg 600x60px
Document › Details

Genome Diagnostics B.V. (GenDx). (12/13/16). "Press Release: GenDx Signs Reseller Agreement with Illumina". Utrecht.

Region Region Europe
Organisations Organisation Genome Diagnostics B.V. (GenDx)
  Group Genome Diagnostics (GenDx) (Group)
  Organisation 2 Illumina Inc. (Nasdaq: ILMN)
  Group Illumina (Group)
Products Product MiSeq™ Personal Sequencing System
  Product 2 HLA diagnostics (HLA typing)
Index term Index term Genome Diagnostics–Illumina: DNA sequencing, 201612– collab GenDx non-excl reseller of Illumina porudcts for HLA sequencing in several countries
Persons Person Mulder, Wietse (Genome Diagnostics 200603 CEO)
  Person 2 Kosoriga, Alina (Genome Diagnostics 2ß01612 Marketing + Communications Associate)

GenDx and Illumina Netherlands BV have recently signed a reseller agreement. According to which GenDx is appointed as a non-exclusive reseller of Illumina products, instruments, such as MiSeq® and MiniSeq® and reagents, as well as maintenance contracts for the field of HLA sequencing in a restricted number of countries, including Benelux, Italy, United Kingdom, Germany and Finland. GenDx is also allowed to deliver these Illumina products in these countries when represented by its own local distributor.

This agreement allows GenDx and its local distributors to support the full workflow for HLA typing laboratories, including the NGS platform, platform specific NGS reagents, as well as dedicated HLA-NGSgo® reagents and NGSengine® software for allelic level HLA typing analyses.

Wietse Mulder PhD, CEO of GenDx commented: “We are very pleased to have signed this agreement and we are looking forward to the collaboration with Illumina. It complements our IVD offering to a full package, as earlier this year GenDx received the CE-IVD marking for the full workflow on Illumina platform. This new relationship with Illumina reinforces our leading position in the field of HLA typing. It also fits to our company’s mission; being an independent organisation with respect to our business partners. At GenDx, our efforts are focused on molecular diagnostics solutions and combination of scientific innovation with reliability, ultimately leading to a better outcome of transplantation”.

Readers of this message, who are interested in HLA typing by NGS and wonder whether they could benefit from this new agreement, can receive more information by contacting their local GenDx distributor or contacting GenDx directly.

About High Resolution HLA Typing

The Human Leukocyte Antigen (HLA) system consists of a large family of highly variable genes and allelic variants, which form the basis of the human immunological defence system. In stem cell transplantation, matching patient and donor is vital, as small differences between HLA alleles may have serious effects on the outcome of transplantation. High resolution typing is a technology, which enables determination of even the smallest of variations in nucleotides, making it ideal for stem cell transplantation purposes. Until today, Sanger sequencing based HLA typing is considered as the golden standard for high resolution typing. GenDx offers SBTexcellerator® and AlleleSEQR® together with the software package SBTengine® for carrying out Sanger sequencing typing.

In 2013, GenDx started as one of the pioneer companies offering Next Generation Sequencing (NGS) strategy, including NGSgo® reagents together with the software package NGSengine®. These products are available for workflows to be used on various different NGS platforms. Both Sanger and NGS techniques analyse the actual DNA sequence of the relevant HLA regions of patient and donor. Moreover, identifying and characterizing new alleles with these techniques is crucial as well. NGS is supposed to become the new golden standard for HLA typing, as data analyses using NGS are becoming easier and faster to interpret and this technique is suitable for higher throughput. NGSengine software has been tested and released in accordance with the IEC62304, the international harmonized standard by the European Union and the United States. It is applicable for medical device software, specifying life cycle requirements for medical software and software within medical devices.

About GenDx

Genome Diagnostics B.V., also known as GenDx, is a Dutch company in Molecular Diagnostics, focused on development, production and sales of innovative assays and analysis software for transplantation medicine and companion diagnostics.

GenDx is specialized in HLA sequencing based typing strategies and offers reagents and software for both Sanger and NGS based approaches. In 2013, GenDx started also selling products for post-transplant monitoring based on real time PCR. Thanks to its extensive in-house expertise, GenDx also offers custom laboratory services for basic and clinical research organisations.

GenDx organises dedicated HLA-SBT training courses worldwide on a regular basis for lab directors, lab managers, scientists and technicians working at tissue typing laboratories, blood banks and donor registries.

GenDx is a spin-off of the University Medical Centre in Utrecht, the Netherlands and was founded in 2005 by Erik Rozemuller PhD, Wietse Mulder PhD and Oscar Schoots PhD, representing the University Medical Centre Utrecht participaties B.V. Further information on GenDx can be found at The global sales of the products is supported by the GenDx team in Utrecht, local distributors or through subsidiaries; GenDx Products, Utrecht (Benelux, Canada and ROW when no local distributor present) and the USA GenDx Prod Inc. team based in Baltimore MD, USA.

GenDx Netherlands

Yalelaan 48
3584 CM Utrecht
Office: +31 30 252 3799


Alina Kosoriga MSc
Marketing & Communication Associate
Phone: +31 30 252 3799

SBTexcellerator®, NGSgo®, AlleleSEQR®, SBTengine® and NGSengine® are registered trademarks of GenDx. GenDx is a registered trade name of Genome Diagnostics B.V. MiSeq®, MiniSeq, and Illumina® are trademarks of Illumina.

Record changed: 2017-01-17


Picture EBD Group BIO-Europe Spring 2019 BES Wien Vienna Austria 273x168px

More documents for Genome Diagnostics (GenDx) (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture BIO Deutschland Biotech Investors Day BID 2019 Würzburg 600x60px

» top